Journal
JOURNAL OF CLINICAL AND TRANSLATIONAL ENDOCRINOLOGY
Volume 1, Issue 1, Pages E19-E25Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jcte.2014.01.003
Keywords
Vitamin D; Hepcidin; Ferroportin; NRAMP1; IL-6; IL-1 beta; Macrophage; Chronic kidney disease; Anemia of inflammation
Categories
Funding
- Emory-Egleston Children's Research Center
- Center for Pediatric Nanomedicine of Emory + Children's Pediatrics Research Center
- [T32 DK007298-32S1]
Ask authors/readers for more resources
Chronic kidney disease affects 40% of adults aged 65 and older. Anemia of CKD is present in 30% of patients with CKD and is associated with increased cardiovascular risk, decreased quality of life, and increased mortality. Hepcidin-25 (hepcidin), the key iron regulating hormone, prevents iron egress from macrophages and thus prevents normal recycling of the iron needed to support erythropoiesis. Hepcidin levels are increased in adults and children with CKD. Vitamin D insufficiency is highly prevalent in CKD and is associated with erythropoietin hyporesponsiveness. Recently, hepcidin levels were found to be inversely correlated with vitamin D status in CKD. The aim of this study was to investigate the role of vitamin D in the regulation of hepcidin expression in vitro and in vivo. This study reports that 1,25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3), the hormonally active form of vitamin D, is associated with decreased hepcidin and increased ferroportin expression in lipopolysaccharide (LPS) stimulated THP-1 cells. 1,25(OH)(2)D-3 also resulted in a dose-dependent decrease in pro-hepcidin cytokines, IL-6 and IL-1 beta, release in vitro. Further, we show that high-dose vitamin D therapy impacts systemic hepcidin levels in subjects with early stage CKD. These data suggest that improvement in vitamin D status is associated with lower systemic concentrations of hepcidin in subjects with CKD. In conclusion, vitamin D regulates the hepcidin-ferroportin axis in macrophages which may facilitate iron egress. Improvement in vitamin D status in patients with CKD may reduce systemic hepcidin levels and may ameliorate anemia of CKD. (C) 2014 Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available